Review



igf2  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems igf2
    Igf2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 69 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+igf+ii/Recombinant+Human+IGF-II%2FIGF2+Protein%2C+CF/us12606639-1424-14-15
    Average 93 stars, based on 69 article reviews
    igf2 - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of α- N -acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts
    Article Snippet: .. 5 μg/ml recombinant human IGF-II (R&D Systems; Minneapolis, MN) or 5 mM D-mannose 6-phosphate (Sigma-Aldrich; St. Louis, MO) was applied to the cells for 10 minutes prior to applying purified rhNAGLU-IGF-II at a final concentration of 160 units/ml. ..

    Article Title: Protein-caloric food restriction affects insulin-like growth factor system in fetal Wistar rat.
    Article Snippet: .. Recombinant human IGF-II (R&D Systems, Abingdon, UK) was used for iodination. .. Western immunoblotting and determination of serum IGFBP-1 and -2 Western immunoblots for enhanced chemiluminescence were performed in polyvinylidene fluoride (PVDF) Immobilon-P membranes (Millipore, Madrid, Spain).

    Article Title: Distinct muscle regenerative capacity of human induced pluripotent stem cell-derived mesenchymal stromal cells in Ullrich congenital muscular dystrophy model mice
    Article Snippet: .. In the IGF2 supplementation group, Recombinant Human IGF-II (292-G2-050, R&D Systems) was added at a concentration of 3.6 ng/ml in MuSC expansion medium on days 1 to 3 and 2.4 ng/ml in MuSC differentiation medium from days 4 to 6, and then cultured. ..

    Article Title: Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho
    Article Snippet: .. The following materials were purchased: fetal bovine serum (FBS) from Bio Whittaker (Walkersville, ML); RPMI-1640 from Life Technologies, Inc. (Grand Island, NY); GGTI-298 and FTI-277 from Calbiochem (La Jolla, CA); recombinant human EGF from AUSTRAL Biologicals (San Ramon, CA); recombinant human SDF-1ß and recombinant human IGF-II from R&D Systems, Inc. (Minneapolis, MN); growth factor reduced Matrigel from Becton-Dickinson Labware (Bedford, MA); transwell chambers from Costar (Cambridge, MA); mouse anti-RhoA monoclonal antibody and goat anti-RhoC polyclonal antibody from Santa Cruz Biotechnology (Santa Cruz, CA); anti-Ras monoclonal antibody from Transduction Laboratories (Lexington, KY); and all other chemicals and reagents from Sigma Chemical Co. (St. Louis, MO). ..

    Article Title: Association Between Paternally Inherited Haplotypes Upstream of the Insulin Gene and Umbilical Cord IGF-II Levels
    Article Snippet: ELISA used 0.3 g/well of a mouse monoclonal anti-human IGF-II obtained from R & D Systems (MAB292, clone #75015), while the detection antibody was 0.025 g/well of a biotin-labeled goat polyclonal anti-human IGF-II (BAF 292 from R & D Systems). .. The standard was recombinant human IGF-II (R & D Systems, 292-G2-050). .. The protocol was that recommended for use with R&D Douset ELISA development procedures.

    Article Title: Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix.
    Article Snippet: .. Recombinant human IGF-II and recombinant human IGFBPs (IGFBP-1 to IGFBP-6) were obtained from R & D Systems (Minneapolis, MN, USA). .. Recombinant human active MMP-7 was obtained from Chemicon International (Temecula, CA, USA).

    Article Title: Insulin-like growth factor (IGF)-II- mediated fibrosis in pathogenic lung conditions
    Article Snippet: IGF1R inhibitor I-OMe-Tyrphostin AG 538 was from Calbiochem (San Diego, CA, USA). .. Recombinant human IGF-II and anti-IGF-II antibody were purchased from R&D Systems (Minneapolis, MN, USA). .. Collagen, Fibronectin, and GAPDH antibodies were from Santa Cruz (Santa Cruz, CA, USA).

    Purification:

    Article Title: Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of α- N -acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts
    Article Snippet: .. 5 μg/ml recombinant human IGF-II (R&D Systems; Minneapolis, MN) or 5 mM D-mannose 6-phosphate (Sigma-Aldrich; St. Louis, MO) was applied to the cells for 10 minutes prior to applying purified rhNAGLU-IGF-II at a final concentration of 160 units/ml. ..

    Concentration Assay:

    Article Title: Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of α- N -acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts
    Article Snippet: .. 5 μg/ml recombinant human IGF-II (R&D Systems; Minneapolis, MN) or 5 mM D-mannose 6-phosphate (Sigma-Aldrich; St. Louis, MO) was applied to the cells for 10 minutes prior to applying purified rhNAGLU-IGF-II at a final concentration of 160 units/ml. ..

    Article Title: Distinct muscle regenerative capacity of human induced pluripotent stem cell-derived mesenchymal stromal cells in Ullrich congenital muscular dystrophy model mice
    Article Snippet: .. In the IGF2 supplementation group, Recombinant Human IGF-II (292-G2-050, R&D Systems) was added at a concentration of 3.6 ng/ml in MuSC expansion medium on days 1 to 3 and 2.4 ng/ml in MuSC differentiation medium from days 4 to 6, and then cultured. ..

    Cell Culture:

    Article Title: Distinct muscle regenerative capacity of human induced pluripotent stem cell-derived mesenchymal stromal cells in Ullrich congenital muscular dystrophy model mice
    Article Snippet: .. In the IGF2 supplementation group, Recombinant Human IGF-II (292-G2-050, R&D Systems) was added at a concentration of 3.6 ng/ml in MuSC expansion medium on days 1 to 3 and 2.4 ng/ml in MuSC differentiation medium from days 4 to 6, and then cultured. ..

    Transduction:

    Article Title: Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho
    Article Snippet: .. The following materials were purchased: fetal bovine serum (FBS) from Bio Whittaker (Walkersville, ML); RPMI-1640 from Life Technologies, Inc. (Grand Island, NY); GGTI-298 and FTI-277 from Calbiochem (La Jolla, CA); recombinant human EGF from AUSTRAL Biologicals (San Ramon, CA); recombinant human SDF-1ß and recombinant human IGF-II from R&D Systems, Inc. (Minneapolis, MN); growth factor reduced Matrigel from Becton-Dickinson Labware (Bedford, MA); transwell chambers from Costar (Cambridge, MA); mouse anti-RhoA monoclonal antibody and goat anti-RhoC polyclonal antibody from Santa Cruz Biotechnology (Santa Cruz, CA); anti-Ras monoclonal antibody from Transduction Laboratories (Lexington, KY); and all other chemicals and reagents from Sigma Chemical Co. (St. Louis, MO). ..



    Similar Products

    93
    R&D Systems igf2
    Igf2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+igf+ii/Recombinant+Human+IGF-II%2FIGF2+Protein%2C+CF/us12606639-1424-14-15
    Average 93 stars, based on 1 article reviews
    igf2 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems igf 2
    PTN regulates endometrial stromal cell decidualization through <t>the</t> <t>IGF-2</t> signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.
    Igf 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+igf+ii/Recombinant+Human+IGF-II%2FIGF2+Protein%2C+CF/pmc13050712-102-22-25
    Average 93 stars, based on 1 article reviews
    igf 2 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    Proteintech recombinant human pro igf ii protein
    PTN regulates endometrial stromal cell decidualization through <t>the</t> <t>IGF-2</t> signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.
    Recombinant Human Pro Igf Ii Protein, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+igf+ii/Animal-free+Recombinant+Human+pro+IGF-II/pmc12996711-84-0-6
    Average 93 stars, based on 1 article reviews
    recombinant human pro igf ii protein - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    R&D Systems igf iir
    PTN regulates endometrial stromal cell decidualization through <t>the</t> <t>IGF-2</t> signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.
    Igf Iir, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+igf+ii/Recombinant+Human+IGF-II+R%2FIGF2R+(aa+43-1365)+Protein%2C+CF/pm41605838-56-8-15
    Average 94 stars, based on 1 article reviews
    igf iir - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant human igf2r protein
    PTN regulates endometrial stromal cell decidualization through <t>the</t> <t>IGF-2</t> signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.
    Recombinant Human Igf2r Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+igf+ii/Recombinant+Human+IGF-II+R%2FIGF2R+Protein%2C+CF/pm41297941-130-0-17
    Average 93 stars, based on 1 article reviews
    recombinant human igf2r protein - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    90
    Boster Bio anti α sma
    PTN regulates endometrial stromal cell decidualization through <t>the</t> <t>IGF-2</t> signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.
    Anti α Sma, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+igf+ii/Human+IGF-II+Recombinant+Protein/pmc12391279-128-7-9
    Average 90 stars, based on 1 article reviews
    anti α sma - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Boster Bio anti a sma
    PTN regulates endometrial stromal cell decidualization through <t>the</t> <t>IGF-2</t> signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.
    Anti A Sma, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+igf+ii/Human+IGF-II+Recombinant+Protein/pm40628202-100-41-42
    Average 90 stars, based on 1 article reviews
    anti a sma - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    PTN regulates endometrial stromal cell decidualization through the IGF-2 signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.

    Journal: Frontiers in Immunology

    Article Title: PTN/IGF-2 signaling modulates endometrial decidualization and immune cell trafficking to facilitate pregnancy maintenance

    doi: 10.3389/fimmu.2026.1790942

    Figure Lengend Snippet: PTN regulates endometrial stromal cell decidualization through the IGF-2 signaling axis. (A) PPI network of PTN, IGF-2, IGFBP1, LIF, PRL, and other decidualization-related genes. (B) The expression levels of PTN and its interacting partners (IGF-2, WNT4, PRL, IGFBP1, and LIF) in the RIF (left) and RPL (right) datasets. (C) Expressions of decidualization-related genes (including IGFBP1 , LIF , PRL , and WNT4 ) in NC or si PTN hESCs after treatment with control vehicle, cAMP, and IGF-2 via RT-qPCR (n = 9). (D) Immunoblotting for PTN, IGFBP1, and PRL expression levels with control vehicle, cAMP, and IGF-2. (E) ELISA for IGF-2 levels with control vehicle, cAMP, and IGF-2. (F) Schematic diagram of the experiments performed using the different treatments of hESCs. Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle, $ compared with si PTN treated with control cAMP (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ####p < 0.0001, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p< 0.0001). PPI, protein–protein interaction; RIF, recurrent implantation failure; RPL, recurrent pregnancy loss; hESCs, human endometrial stromal cells; cAMP, cyclic adenosine monophosphate.

    Article Snippet: The remaining cells were digested with trypsin and inoculated into a new culture dish, and they were treated with control vehicle or IGF-2 (50 ng/mL, R&D Systems, Minneapolis, MN, USA, 292-G2) for 48 h and then collected for quantitative real-time polymerase chain reaction (qRT-PCR).

    Techniques: Expressing, Control, Quantitative RT-PCR, Western Blot, Enzyme-linked Immunosorbent Assay

    IGF-2 promotes decidualization and rescues decidualization defects caused by PTN deficiency. (A) Schematic diagram of the experiments performed using the different treatments of ESCs isolated from endometrium of RIF and RPL patients. (B, C) RT-qPCR analysis of levels of decidualization-related genes in ESCs isolated from endometrium of RIF (B) and RPL (C) patients after IGF-2 (50 ng/mL) treatment for 48 h (n = 9). (D) The flowchart depicts the steps involved in establishing a mouse model of intrauterine perfusion with siRNA-mediated knockdown of PTN and then supplemented with IGF-2 (50 ng/mL) through tail vein injection. (E) Expression of PTN after Ptn knockdown and supplemented with control vehicle or IGF-2 (50 ng/mL) in the mouse endometrium, measured by immunofluorescence, and quantitative analysis of immunofluorescence was performed (n = 6). (F) RT-qPCR analysis of levels of decidualization-related genes after Ptn knockdown and supplemented with control vehicle or IGF-2 (50 ng/mL) in the mouse endometrium (n = 6). Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p< 0.0001, ## p < 0.01, ### p < 0.001, #### p < 0.0001). ESCs, endometrial stromal cells; PPI, protein–protein interaction; RIF, recurrent implantation failure.

    Journal: Frontiers in Immunology

    Article Title: PTN/IGF-2 signaling modulates endometrial decidualization and immune cell trafficking to facilitate pregnancy maintenance

    doi: 10.3389/fimmu.2026.1790942

    Figure Lengend Snippet: IGF-2 promotes decidualization and rescues decidualization defects caused by PTN deficiency. (A) Schematic diagram of the experiments performed using the different treatments of ESCs isolated from endometrium of RIF and RPL patients. (B, C) RT-qPCR analysis of levels of decidualization-related genes in ESCs isolated from endometrium of RIF (B) and RPL (C) patients after IGF-2 (50 ng/mL) treatment for 48 h (n = 9). (D) The flowchart depicts the steps involved in establishing a mouse model of intrauterine perfusion with siRNA-mediated knockdown of PTN and then supplemented with IGF-2 (50 ng/mL) through tail vein injection. (E) Expression of PTN after Ptn knockdown and supplemented with control vehicle or IGF-2 (50 ng/mL) in the mouse endometrium, measured by immunofluorescence, and quantitative analysis of immunofluorescence was performed (n = 6). (F) RT-qPCR analysis of levels of decidualization-related genes after Ptn knockdown and supplemented with control vehicle or IGF-2 (50 ng/mL) in the mouse endometrium (n = 6). Data are presented as mean ± SEM and analyzed using t-test or one-way ANOVA test. * compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p< 0.0001, ## p < 0.01, ### p < 0.001, #### p < 0.0001). ESCs, endometrial stromal cells; PPI, protein–protein interaction; RIF, recurrent implantation failure.

    Article Snippet: The remaining cells were digested with trypsin and inoculated into a new culture dish, and they were treated with control vehicle or IGF-2 (50 ng/mL, R&D Systems, Minneapolis, MN, USA, 292-G2) for 48 h and then collected for quantitative real-time polymerase chain reaction (qRT-PCR).

    Techniques: Isolation, Quantitative RT-PCR, Knockdown, Injection, Expressing, Control, Immunofluorescence

    PTN deficiency induces endometrial immune imbalance and leads to adverse pregnancy outcomes, which can be partially reversed by IGF-2. (A) PPI network of PTN, IGF-2, CXCR4, CD4, CD8, CD56, and other immunoregulators. (B, C) Flow cytometry analysis (B) and statistical quantification (C) of cell populations of NK cells and T cells, and the expression levels of CD16, CXCR4, and GZMB in NK cell form the endometrial tissues of NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) (n = 6). (D) The flowchart depicts the steps involved in establishing a mouse model of intrauterine perfusion with siRNA-mediated knockdown of Ptn and then supplemented with IGF-2 (50 ng/mL) through tail vein injection for 2 days; then, these female mice were mated with fertile male mice; analysis of fertility, including pregnancy rate, IF, and fluorescence-activated cell sorting (FACS). were performed at gestational day 13.5. (E) Representative images of uteri from pregnant mice in the NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) at gestational day 13.5 (n = 6) (arrow shows the absorption site). (F) Pregnancy rate (%) in NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) (n = 15). (G) Quantification of embryo numbers (left) and absorption rate (right) per mouse in NC (n = 13) and si PTN mice treated with control vehicle (n = 6) or IGF-2 (50 ng/mL) (n = 11) at gestational day 13.5. Data are presented as mean ± SEM and analyzed using one-way ANOVA test or χ 2 test. * Compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ## p < 0.01, ### p < 0.001, #### p < 0.0001). IF, immunofluorescence.

    Journal: Frontiers in Immunology

    Article Title: PTN/IGF-2 signaling modulates endometrial decidualization and immune cell trafficking to facilitate pregnancy maintenance

    doi: 10.3389/fimmu.2026.1790942

    Figure Lengend Snippet: PTN deficiency induces endometrial immune imbalance and leads to adverse pregnancy outcomes, which can be partially reversed by IGF-2. (A) PPI network of PTN, IGF-2, CXCR4, CD4, CD8, CD56, and other immunoregulators. (B, C) Flow cytometry analysis (B) and statistical quantification (C) of cell populations of NK cells and T cells, and the expression levels of CD16, CXCR4, and GZMB in NK cell form the endometrial tissues of NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) (n = 6). (D) The flowchart depicts the steps involved in establishing a mouse model of intrauterine perfusion with siRNA-mediated knockdown of Ptn and then supplemented with IGF-2 (50 ng/mL) through tail vein injection for 2 days; then, these female mice were mated with fertile male mice; analysis of fertility, including pregnancy rate, IF, and fluorescence-activated cell sorting (FACS). were performed at gestational day 13.5. (E) Representative images of uteri from pregnant mice in the NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) at gestational day 13.5 (n = 6) (arrow shows the absorption site). (F) Pregnancy rate (%) in NC and si PTN mice treated with control vehicle or IGF-2 (50 ng/mL) (n = 15). (G) Quantification of embryo numbers (left) and absorption rate (right) per mouse in NC (n = 13) and si PTN mice treated with control vehicle (n = 6) or IGF-2 (50 ng/mL) (n = 11) at gestational day 13.5. Data are presented as mean ± SEM and analyzed using one-way ANOVA test or χ 2 test. * Compared with NC treated with control vehicle, # compared with si PTN treated with control vehicle (NS, no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ## p < 0.01, ### p < 0.001, #### p < 0.0001). IF, immunofluorescence.

    Article Snippet: The remaining cells were digested with trypsin and inoculated into a new culture dish, and they were treated with control vehicle or IGF-2 (50 ng/mL, R&D Systems, Minneapolis, MN, USA, 292-G2) for 48 h and then collected for quantitative real-time polymerase chain reaction (qRT-PCR).

    Techniques: Flow Cytometry, Expressing, Control, Knockdown, Injection, Fluorescence, FACS, Immunofluorescence